Clinical trial

Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

NCT03315871

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-03-20

PhasePHASE2

Study timeline

Study start (actual)2018-03-20Date precision: day

Registry last updated2025-06-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Antigen direct immunotherapy: PROSTVAC-VBIOLOGICAL

Antigen direct immunotherapy: PROSTVAC-FBIOLOGICAL

MSB0011359C (M7824)DRUG

Antigen direct immunotherapy: CV301BIOLOGICAL

CT scan of chestDIAGNOSTIC_TEST

CT scan of abdomen/pelvisDIAGNOSTIC_TEST

MRIDIAGNOSTIC_TEST

PSMADIAGNOSTIC_TEST

Bone scanDIAGNOSTIC_TEST

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

BethesdaMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03315871 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.